Literature DB >> 7065375

Comparative study of bioavailabilities of different phenytoin preparations.

Y Fukuyama, H Kitahara, T Goto.   

Abstract

A comparative study of the serum phenytoin (PHT) concentration levels during the treatment with different PHT preparations (powders or tablets) manufactured by two Japanese pharmaceutical companies gave the following results: 1) The serum PHT concentration levels (S in microgram/ml) of children (aged 7-11) who were taking Company A's powder and phenobarbital were less than 2.0 microgram/ml in 21 out of 24 (87.5%) cases without correlation with the dosage (D in mg/kg). The levels in 19 children of the same ages taking Company A's tablets showed significant correlation with the dosage, and the regression line was S = 1.9D - 2.65 (r = 0.86). 2) In 33 cases, previously administered Company A's powder was substituted with different PHT preparations of the same or a lesser dosage; Company A's tablet in group I; powderized Company A's tablet in group II: Company B's powder in group III; and Company B's tablet (solid or powderized) in group IV. In all cases, the PHT S/D ratio increased after the substitution and the mean increase +/- SD was 1.3 +/- 1.2 (p less than 0.001) for group I, 1.0 +/- 0.1 (p less than 0.001) for group II, 0.45 +/- 0.1 (p less than 0.005) for group III, and 1.6 +/- 0.4 (p less than 0.015) for group IV. 3) Tested in five patients using three specially prepared phenytoin powders with different particle sizes clearly demonstrated the fact that the smaller the PHT particle, the higher the PHT S/D ratio. 4) It was suggested that the factors other than particle size of the drug should be taken into consideration in the interpretation of different bioavailabilities of different PHT preparations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065375

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  2 in total

Review 1.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

2.  Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products.

Authors:  Gopal Pawar; Fang Wu; Liang Zhao; Lanyan Fang; Gilbert J Burckart; Kairui Feng; Youssef M Mousa; Franci Naumann; Hannah K Batchelor
Journal:  AAPS J       Date:  2021-04-21       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.